<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02700464</url>
  </required_header>
  <id_info>
    <org_study_id>UC-EpiCheck-FDA-01</org_study_id>
    <nct_id>NCT02700464</nct_id>
  </id_info>
  <brief_title>The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma</brief_title>
  <official_title>The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma: A Multicenter, Prospective Blinded Pivotal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nucleix Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nucleix Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial to determine the efficacy (sensitivity and specificity) of the Bladder
      EpiCheck test compared to the gold standard cystoscopy and pathology in patients under
      monitoring for recurrence of bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Bladder EpiCheck test is an in vitro diagnostic device for the detection of DNA
      methylation patterns in urine that are associated with bladder cancer. It is intended for use
      as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy
      inpatients previously diagnosed with bladder cancer This is a, multicenter, prospective,
      blinded study to evaluate the efficacy (sensitivity and specificity) of a novel methylation
      test for the detection of recurrent Urothelial Cell Carcinoma in patients with a history of
      bladder cancer undergoing surveillance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specificity of Bladder EpiCheck Urine Test Kit (the proportion of negatives that are correctly identified as such by the gold standard)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity of Bladder EpiCheck Urine Test Kit (The proportion of positives that are correctly identified as such by the gold standard)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Bladder EpiCheck Urine Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bladder EpiCheck Urine Test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gold Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cystoscopy and pathology</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bladder EpiCheck Urine Test</intervention_name>
    <description>The Bladder EpiCheck test is an in vitro diagnostic device for the detection of DNA methylation patterns in urine that are associated with bladder cancer. It is intended for use as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy inpatients previously diagnosed with bladder cancer</description>
    <arm_group_label>Bladder EpiCheck Urine Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cystoscopy and pathology</intervention_name>
    <description>Routine cystoscopy for bladder cancer recurrence and pathology confirmation for patients with positive cystoscopy</description>
    <arm_group_label>Gold Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any male or female patient diagnosed with incident or recurrent Urothelial Cell
             Carcinoma and undergoing surveillance at 3 month intervals.

          -  Has had all urothelial cell carcinoma tumor resected within the past 12 months

          -  Has a plan for cystoscopic surveillance (adjuvant intravesical therapy allowed)

          -  Able to provide legally effective informed consent

          -  Able to produce 45mL of urine

        Exclusion Criteria:

          -  Planning to undergo radical cystectomy or chemotherapy-radiation for Urothelial Cell
             Carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shmulik Adler, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Nucleix Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shmulik Adler, MSc</last_name>
    <phone>011-972-8-9161616</phone>
    <phone_ext>117</phone_ext>
    <email>shmulik@nucleix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Hammond</last_name>
      <phone>443-471-5749</phone>
      <email>rhammond@cua.md</email>
    </contact>
    <investigator>
      <last_name>Anup Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Urology</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diane Kachel</last_name>
      <phone>612-819-0533</phone>
      <email>DKachel@mnurology.com</email>
    </contact>
    <investigator>
      <last_name>Peter Sershon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urological Surgeons of Long Island</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Gerrity</last_name>
      <phone>516-742-3200</phone>
      <phone_ext>302</phone_ext>
      <email>dgerrity@prohealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Lumerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Lech</last_name>
      <phone>919-681-7348</phone>
      <email>denise.lech@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Brant Inman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Homann</last_name>
      <phone>216-444-0124</phone>
      <email>HOMANNJ@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Ryan Berglund, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Steele, RN</last_name>
      <phone>615-343-2120</phone>
      <email>pamela.steele@Vanderbilt.Edu</email>
    </contact>
    <investigator>
      <last_name>Moses Kelvin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Cruz</last_name>
      <phone>210-617-4116</phone>
      <email>Jennifer.Cruz@urologysa.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Saltzstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandria Lahdya</last_name>
      <phone>949-294-9084</phone>
      <email>azlahdya@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UHN, Princess Margret Cancer center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parisa Sairafi</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>5514</phone_ext>
      <email>Parisa.Sairafi@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Neil Fleshner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2016</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

